DISCUSSION
skeletal muscle mass
ASM / heightWe found that ASM / heightThe present study shows that SGLT2i administration might have an unfavorable effect on skeletal muscle mass in older men with type 1 diabetes. It is widely known that the absolute amount of skeletal muscle mass is higher in men than in womenGood glycemic control in individuals with type 1 diabetes has been established to prevent the development of microvascular diseasesSkeletal muscle function is impaired in individuals with type 1 diabetesDecreases in bodyweight, BMI and body fat, and increases in TBR, were observed with the start of SGLT2i treatment, and these changes were correlated. The decrease in body fat might represent energy production from adipose tissue due to hypoglycemiaThe key limitations of the present study were that it was a post‐hoc analysis based on short‐term results with no control participants. Furthermore, we did not collect indicators of muscle function, such as grip strength and walking speed. In contrast, our analysis provides valuable evidence of changes in the two skeletal muscle mass parameters. The study sample size of 36 participants was not enough to generalize the findings from this study. In contrast, it is necessary to accumulate the effects of dapagliflozin in type 1 diabetes patients. Indeed, Martínez‐Montoro 